董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John J. Borer | 男 | Independent Director | 69 | 8.73万美元 | 未持股 | 2025-08-25 |
| Beth J. Hoffman | 女 | Independent Director | 69 | 8.43万美元 | 未持股 | 2025-08-25 |
| Kevin D. Weber | 男 | Independent Director | 68 | 8.83万美元 | 未持股 | 2025-08-25 |
| Heikki Lanckriet | 男 | Director | 49 | 6.03万美元 | 未持股 | 2025-08-25 |
| Hermann Luebbert | -- | Executive Chairman of the Board and Chief Executive Officer | -- | 87.32万美元 | 31.11 | 2025-08-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eugene Fredrick Leffler, III | 男 | Chief Financial Officer and Principal Accounting Officer | 42 | 7.97万美元 | 未持股 | 2025-08-25 |
| George Jones | 男 | Chief Commercial Officer | 52 | 15.76万美元 | 未持股 | 2025-08-25 |
| Hermann Luebbert | -- | Executive Chairman of the Board and Chief Executive Officer | -- | 87.32万美元 | 31.11 | 2025-08-25 |
董事简历
中英对照 | 中文 | 英文- John J. Borer
-
此次发行完成后，John J.Borer将成为我们董事会的成员。2012年以来，他一直担任The Benchmark Company，LLC的高级董事总经理兼投资银行联席主管，该公司是该产品的首席账簿管理经理之一。他曾担任Rodman&Renshaw公司的首席执行官兼投资银行业务主管，也曾担任Security Pacific Business Credit公司和Barclays American Business Credit公司的高级职务。自2016年5月起，Borer先生还曾在Biofrontera AG的监事会任职。他拥有加州洛杉矶Loyola Law School的法学博士学位，以及加州大学戴维斯分校的农业经济学学位。
John J. Borer,became a member of Biofrontera Inc. Board of Directors in November 2021. Since 2012, he has been the Senior Managing Director and Co-Head of Investment Banking at The Benchmark Company, LLC. He was formerly the Chief Executive Officer and Head of Investment Banking at Rodman & Renshaw and has held senior positions at Security Pacific Business Credit and Barclays American Business Credit. Mr. Borer has also served on the Supervisory Board of Biofrontera AG since May 2016 until December 2021. He holds a Juris Doctor from Loyola Law School in Los Angeles, California and a B.S. in Agricultural Economics from The University of California, Davis. - 此次发行完成后，John J.Borer将成为我们董事会的成员。2012年以来，他一直担任The Benchmark Company，LLC的高级董事总经理兼投资银行联席主管，该公司是该产品的首席账簿管理经理之一。他曾担任Rodman&Renshaw公司的首席执行官兼投资银行业务主管，也曾担任Security Pacific Business Credit公司和Barclays American Business Credit公司的高级职务。自2016年5月起，Borer先生还曾在Biofrontera AG的监事会任职。他拥有加州洛杉矶Loyola Law School的法学博士学位，以及加州大学戴维斯分校的农业经济学学位。
- John J. Borer,became a member of Biofrontera Inc. Board of Directors in November 2021. Since 2012, he has been the Senior Managing Director and Co-Head of Investment Banking at The Benchmark Company, LLC. He was formerly the Chief Executive Officer and Head of Investment Banking at Rodman & Renshaw and has held senior positions at Security Pacific Business Credit and Barclays American Business Credit. Mr. Borer has also served on the Supervisory Board of Biofrontera AG since May 2016 until December 2021. He holds a Juris Doctor from Loyola Law School in Los Angeles, California and a B.S. in Agricultural Economics from The University of California, Davis.
- Beth J. Hoffman
-
此次发行完成后，Beth J.Hoffman将成为我们董事会的成员。自2019年7月以来，她一直是Semperfi Accounting Services，LLC的管理合伙人。在此之前，她于2017年2月至10月担任Velcro Companies的副总裁，财务和财务总监，并于2015年6月至2017年2月担任CRISPR Therapeutics的副总裁和财务总监。Wedge女士是一位财务主管，拥有超过25年的公共和私营部门经验，包括丰富的制造、公用事业、医疗设备、生物制药和公用事业经验。她拥有加州萨克拉门托的加州州立大学的工商管理硕士学位。她持有活跃的注册会计师执照，也是注册特许全球管理会计师。
Beth J. Hoffman,became a member of Biofrontera Inc. Board of Directors in November 2021. Dr. Hoffman is the founder, and, since 2015, has been the President and Chief Executive Officer, of Origami Therapeutics, Inc., in San Diego, California. Dr. Hoffman has over 20 years of experience in drug discovery and development. Dr. Hoffman has made major contributions to the launch of two first-in-class drugs and two best-in-class drugs for Cystic Fibrosis. Dr. Hoffman holds her Ph.D. in Biology from The Johns Hopkins University in Baltimore, Maryland. - 此次发行完成后，Beth J.Hoffman将成为我们董事会的成员。自2019年7月以来，她一直是Semperfi Accounting Services，LLC的管理合伙人。在此之前，她于2017年2月至10月担任Velcro Companies的副总裁，财务和财务总监，并于2015年6月至2017年2月担任CRISPR Therapeutics的副总裁和财务总监。Wedge女士是一位财务主管，拥有超过25年的公共和私营部门经验，包括丰富的制造、公用事业、医疗设备、生物制药和公用事业经验。她拥有加州萨克拉门托的加州州立大学的工商管理硕士学位。她持有活跃的注册会计师执照，也是注册特许全球管理会计师。
- Beth J. Hoffman,became a member of Biofrontera Inc. Board of Directors in November 2021. Dr. Hoffman is the founder, and, since 2015, has been the President and Chief Executive Officer, of Origami Therapeutics, Inc., in San Diego, California. Dr. Hoffman has over 20 years of experience in drug discovery and development. Dr. Hoffman has made major contributions to the launch of two first-in-class drugs and two best-in-class drugs for Cystic Fibrosis. Dr. Hoffman holds her Ph.D. in Biology from The Johns Hopkins University in Baltimore, Maryland.
- Kevin D. Weber
-
Kevin D. Weber于2022年3月成为Biofrontera Inc.董事会成员。Weber先生是一位经验丰富的制药主管，他为Biofrontera带来了30多年的执行和商业化经验，并在产品营销方面拥有专长。他曾在一系列治疗领域工作，包括临床和美容皮肤病学、疼痛管理、先天代谢错误和呼吸医学。他最近从Skysis的负责人职位上退休，Skysis是一家专注于生物技术的品牌管理咨询公司，之前曾担任石蜡国际的首席执行官。在加入石蜡公司之前，Weber先生曾在Depomed、Hyperion Therapeutics和Medicis Pharmaceuticals担任高级主管和营销职务。2016年至2021年，Weber先生担任Biofrontera AG监事会成员。韦伯先生曾在美国疼痛医学学会基金会、美国慢性疼痛协会和亚利桑那州生物工业协会董事会任职。他拥有西密歇根大学工商管理学士学位。
Kevin D. Weber,became a member of Biofrontera Inc. Board of Directors in March 2022.He has worked in a range of therapeutic areas including clinical and aesthetic dermatology, pain management, inborn errors of metabolism and respiratory medicine. He recently retired from his position as a Principal at Skysis, a biotech-focused brand management consulting practice, and previously served as CEO of Paraffin International. Prior to Paraffin, Mr. Weber served in senior executive and marketing roles at Depomed, Hyperion Therapeutics and Medicis Pharmaceuticals. From 2016 to 2021 Mr. Weber served as a member of the supervisory board of Biofrontera AG. Mr. Weber previously served on the Boards of Directors of the American Academy of Pain Medicine Foundation, the American Chronic Pain Association and the Arizona Bioindustry Association. He holds a B.S. in Business Administration from Western Michigan University. - Kevin D. Weber于2022年3月成为Biofrontera Inc.董事会成员。Weber先生是一位经验丰富的制药主管，他为Biofrontera带来了30多年的执行和商业化经验，并在产品营销方面拥有专长。他曾在一系列治疗领域工作，包括临床和美容皮肤病学、疼痛管理、先天代谢错误和呼吸医学。他最近从Skysis的负责人职位上退休，Skysis是一家专注于生物技术的品牌管理咨询公司，之前曾担任石蜡国际的首席执行官。在加入石蜡公司之前，Weber先生曾在Depomed、Hyperion Therapeutics和Medicis Pharmaceuticals担任高级主管和营销职务。2016年至2021年，Weber先生担任Biofrontera AG监事会成员。韦伯先生曾在美国疼痛医学学会基金会、美国慢性疼痛协会和亚利桑那州生物工业协会董事会任职。他拥有西密歇根大学工商管理学士学位。
- Kevin D. Weber,became a member of Biofrontera Inc. Board of Directors in March 2022.He has worked in a range of therapeutic areas including clinical and aesthetic dermatology, pain management, inborn errors of metabolism and respiratory medicine. He recently retired from his position as a Principal at Skysis, a biotech-focused brand management consulting practice, and previously served as CEO of Paraffin International. Prior to Paraffin, Mr. Weber served in senior executive and marketing roles at Depomed, Hyperion Therapeutics and Medicis Pharmaceuticals. From 2016 to 2021 Mr. Weber served as a member of the supervisory board of Biofrontera AG. Mr. Weber previously served on the Boards of Directors of the American Academy of Pain Medicine Foundation, the American Chronic Pain Association and the Arizona Bioindustry Association. He holds a B.S. in Business Administration from Western Michigan University.
- Heikki Lanckriet
-
Heikki Lanckriet，于2023年7月成为Biofrontera Inc.董事会成员。Lanckriet博士目前担任英国4basebio PLC的首席执行官和首席科学官，该公司是一家上市公司，从事合成DNA和RNA产品的研究、开发、制造和商业化，目标非病毒载体解决方案于2021年从Expedeon AG分拆出来。2020年，Lanckriet博士牵头将Expedeon的蛋白质组学和免疫学业务出售给了ABCAM PLC。早些时候，Lanckriet博士是Novexin的创始人和首席科学官，后来过渡到首席运营官。Lanckriet博士还曾在2invest AG和Sygnis AG担任首席执行官和首席科学官。Lanckriet博士拥有英国剑桥大学化学工程学博士学位和比利时根特大学化学工程学硕士学位。他撰写了多篇科学论文，发表在同行评审的医学和科学期刊上，是多项专利的指定发明人。
Heikki Lanckriet,became a member of Biofrontera Inc. Board of Directors in July 2023. Dr. Lanckriet currently serves as Chief Executive Officer and Chief Scientific Officer of 4basebio PLC, UK, a publicly traded company that engages in the research, development, manufacturing and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions which was spun out of Expedeon AG in 2021. In 2020, Dr. Lanckriet led the sale of Expedeon's proteomics and immunology business to Abcam PLC. Earlier, Dr. Lanckriet was Founder and Chief Scientific Officer of Novexin, later transitioning to Chief Operating Officer. Dr. Lanckriet also held roles as Chief Executive Officer and Chief Scientific Officer at 2invest AG and Sygnis AG. Dr. Lanckriet holds a Ph.D. in Chemical Engineering from the University of Cambridge in the U.K. and a M.Eng. in Chemical Engineering from the University of Ghent in Belgium. He has authored several scientific papers that have been published in peer-reviewed medical and scientific journals and is a named inventor on a multitude of patents. - Heikki Lanckriet，于2023年7月成为Biofrontera Inc.董事会成员。Lanckriet博士目前担任英国4basebio PLC的首席执行官和首席科学官，该公司是一家上市公司，从事合成DNA和RNA产品的研究、开发、制造和商业化，目标非病毒载体解决方案于2021年从Expedeon AG分拆出来。2020年，Lanckriet博士牵头将Expedeon的蛋白质组学和免疫学业务出售给了ABCAM PLC。早些时候，Lanckriet博士是Novexin的创始人和首席科学官，后来过渡到首席运营官。Lanckriet博士还曾在2invest AG和Sygnis AG担任首席执行官和首席科学官。Lanckriet博士拥有英国剑桥大学化学工程学博士学位和比利时根特大学化学工程学硕士学位。他撰写了多篇科学论文，发表在同行评审的医学和科学期刊上，是多项专利的指定发明人。
- Heikki Lanckriet,became a member of Biofrontera Inc. Board of Directors in July 2023. Dr. Lanckriet currently serves as Chief Executive Officer and Chief Scientific Officer of 4basebio PLC, UK, a publicly traded company that engages in the research, development, manufacturing and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions which was spun out of Expedeon AG in 2021. In 2020, Dr. Lanckriet led the sale of Expedeon's proteomics and immunology business to Abcam PLC. Earlier, Dr. Lanckriet was Founder and Chief Scientific Officer of Novexin, later transitioning to Chief Operating Officer. Dr. Lanckriet also held roles as Chief Executive Officer and Chief Scientific Officer at 2invest AG and Sygnis AG. Dr. Lanckriet holds a Ph.D. in Chemical Engineering from the University of Cambridge in the U.K. and a M.Eng. in Chemical Engineering from the University of Ghent in Belgium. He has authored several scientific papers that have been published in peer-reviewed medical and scientific journals and is a named inventor on a multitude of patents.
- Hermann Luebbert
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Eugene Fredrick Leffler, III
Eugene Fredrick Leffler，III被任命为Biofrontera Inc.Chief Financial Officer，自2022年10月24日起生效。Leffler先生是一位经验丰富的财务主管，拥有15年的领导、财务管理、咨询和运营经验，曾在一系列私营和公共组织工作，包括成长阶段、私人股本和财富100强公司。在加入Biofrontera担任Chief Financial Officer之前，Leffler先生自2022年1月起在麦肯锡公司担任高级经理，并于2015年9月至2019年11月担任协理和高级经理等不同职务。在重新加入麦肯锡公司之前，Leffler先生于2020年8月至2022年1月担任FTI咨询公司的企业融资与重组高级总监。在加入FTI咨询公司之前，他于2019年11月至2020年8月担任Rockcreek数据与分析副总裁。在其职业生涯的早期，莱夫勒曾在通用电气和太阳爱迪生公司担任过多个财务职位。Leffler先生在俄亥俄州立大学费舍尔商学院获得金融和经济学学士学位，在杜克大学富夸商学院获得工商管理硕士学位。
Eugene Fredrick Leffler, III was appointed as Biofrontera Inc.'s Chief Financial Officer effective October 24 2022. Mr. Leffler is an experienced financial executive with 15 years of leadership, financial management, consultancy and operations experience across a range of private and public organizations, including growth-stage, private equity and Fortune 100 companies. Prior to joining Biofrontera Inc. as Chief Financial Officer, Mr. Leffler served as a Senior Manager at McKinsey & Company since January 2022 as well as in different capacities, including Associate and Senior Manager from September 2015 to November 2019. Prior to rejoining McKinsey & Company, Mr. Leffler served as the Senior Director, Corporate Finance & Restructuring of FTI Consulting from August 2020 to January 2022. Prior to joining FTI Consulting, he served as Vice President, Data & Analytics of Rockcreek from November 2019 to August 2020. Earlier in his career, Mr. Leffler held various financial positions at General Electric and Sun Edison. Mr. Leffler received a BSBA in finance and economics from The Ohio State University Fisher School of Business, and an MBA from Duke University's Fuqua School of Business.- Eugene Fredrick Leffler，III被任命为Biofrontera Inc.Chief Financial Officer，自2022年10月24日起生效。Leffler先生是一位经验丰富的财务主管，拥有15年的领导、财务管理、咨询和运营经验，曾在一系列私营和公共组织工作，包括成长阶段、私人股本和财富100强公司。在加入Biofrontera担任Chief Financial Officer之前，Leffler先生自2022年1月起在麦肯锡公司担任高级经理，并于2015年9月至2019年11月担任协理和高级经理等不同职务。在重新加入麦肯锡公司之前，Leffler先生于2020年8月至2022年1月担任FTI咨询公司的企业融资与重组高级总监。在加入FTI咨询公司之前，他于2019年11月至2020年8月担任Rockcreek数据与分析副总裁。在其职业生涯的早期，莱夫勒曾在通用电气和太阳爱迪生公司担任过多个财务职位。Leffler先生在俄亥俄州立大学费舍尔商学院获得金融和经济学学士学位，在杜克大学富夸商学院获得工商管理硕士学位。
- Eugene Fredrick Leffler, III was appointed as Biofrontera Inc.'s Chief Financial Officer effective October 24 2022. Mr. Leffler is an experienced financial executive with 15 years of leadership, financial management, consultancy and operations experience across a range of private and public organizations, including growth-stage, private equity and Fortune 100 companies. Prior to joining Biofrontera Inc. as Chief Financial Officer, Mr. Leffler served as a Senior Manager at McKinsey & Company since January 2022 as well as in different capacities, including Associate and Senior Manager from September 2015 to November 2019. Prior to rejoining McKinsey & Company, Mr. Leffler served as the Senior Director, Corporate Finance & Restructuring of FTI Consulting from August 2020 to January 2022. Prior to joining FTI Consulting, he served as Vice President, Data & Analytics of Rockcreek from November 2019 to August 2020. Earlier in his career, Mr. Leffler held various financial positions at General Electric and Sun Edison. Mr. Leffler received a BSBA in finance and economics from The Ohio State University Fisher School of Business, and an MBA from Duke University's Fuqua School of Business.
- George Jones
George Jones，自2021年起在UpScriptHealth担任首席运营官。在UpScriptHealth之前，琼斯先生自2015年起在Currax Pharmaceuticals担任高级商业职务。
George Jones,served as Chief Operating Officer at UpScriptHealth since 2021. Prior to UpScriptHealth, Mr. Jones held senior commercial roles at Currax Pharmaceuticals since 2015.- George Jones，自2021年起在UpScriptHealth担任首席运营官。在UpScriptHealth之前，琼斯先生自2015年起在Currax Pharmaceuticals担任高级商业职务。
- George Jones,served as Chief Operating Officer at UpScriptHealth since 2021. Prior to UpScriptHealth, Mr. Jones held senior commercial roles at Currax Pharmaceuticals since 2015.
- Hermann Luebbert
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介